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Background: 4-Methylumbelliferone (4-MU), a hyaluronan (HA) synthesis inhibitor, has antitumor activity in cancer
cells. However, few studies have focused on its effects on ovarian cancer. The aim of this study was to investigate
the effects of 4-MU on ovarian cancer and to elucidate its mechanism of action.
Methods: The HRA human ovarian serous adenocarcinoma cell line was used in this study. The effects of 4-MU on
cell proliferation, migration, and invasion were determined by using in vitro assays as well as an in vivo rat peritoneal
carcinomatosis model. The expression of HA synthase (HAS), CD44 HA receptor, vascular endothelial growth factor (VEGF),
and thymidine phosphorylase (TP) mRNA in HRA cells was analyzed by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR).
Results: 4-MU administration inhibited the growth of peritoneal tumors and significantly prolonged survival. In vitro
experiments showed that 4-MU inhibited HRA cell proliferation in a dose-dependent manner, while it did not affect HRA
cell invasion and migration. 4-MU significantly decreased TP mRNA expression in HRA cells. On the other hand, since
HAS2, CD44, and VEGF endogenous mRNA expression levels were very low in HRA cells, it was impossible to evaluate the
effect of 4-MU treatment.
Conclusions: These results suggest that 4-MU exerts its antitumor effect on ovarian cancer through suppressing TP
expression.
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Epithelial ovarian cancer is the most lethal malignancy
in women because it is usually diagnosed at the severe
peritonitis carcinomatosa advanced stage of the disease.
Epithelial ovarian cancer is the sixth and eighth leading
cause of cancer mortality among women in developed
and developing countries [1]. The worldwide estimated
number of new ovarian cancer cases increased from
137,600 in 1980 to 225,000 in 2008 [1]. There are differ-
ent strategies for treating advanced ovarian cancer.
Cytoreductive surgery followed by adjuvant chemother-
apy is commonly recommended as the primary treat-
ment for advanced (stage III/IV) epithelial ovarian cancer.* Correspondence: yokoyama@cc.hirosaki-u.ac.jp
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unless otherwise stated.Alternatively, neo-adjuvant chemotherapy may be selected
for patients with bulky stage III/IV tumors for which sur-
gery would be suboptimal. Postoperatively, the combin-
ation of a taxane and carboplatin is used as first-line
chemotherapy [2]. Moreover, taxanes, carboplatin, cis-
platin, liposomal doxorubicin, gemcitabine, etoposide, or
topotecanin in combination or as single agents are accept-
able as second- or third-line therapies for relapsed disease.
Thus, chemotherapy plays an important role in ovarian
cancer treatment. However, some patients with advanced
ovarian cancer develop chemoresistance, which makes
it difficult to prevent the development of peritonitis carci-
nomatosa, leading to reduced quality of life and a poor
prognosis. Since the effects of the available treatments for
ovarian cancer are restricted, it is necessary to develop
new drugs.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bevacizumab [3], poly(adenosine diphosphate-ribose) poly-
merase inhibitors [4], farletuzumab [5], and trabectedin
[6], are effective for ovarian cancer treatment and some
of them are used clinically. However, because of concerns,
including adverse reactions and cost-effectiveness, the clin-
ical advantages of targeted drugs for ovarian cancer treat-
ment remain unclear.
Hyaluronan (HA) is a high-molecular-weight glycosami-
noglycan and a major component of the pericellular
matrix. HA, which is synthesized by hyaluronan synthase
(HAS), regulates multiple cellular functions [7]. The cellu-
lar effects of HA are mediated through the CD44 HA re-
ceptor [8]. CD44 has also been recently recognized as a
cancer stem cell surface marker in several cancer types
[9,10], and CD44 expression in cancer cells promoted bone
metastasis by enhancing tumorigenicity, cell migration and
invasion, and HA production [11]. 4-Methylumbelliferone
(4-MU) is an HA synthesis inhibitor [7]. 4-MU blocks HA
synthesis by inhibiting glucuronidation by endogenous glu-
curonosyltransferase, which results in depletion of uridine
diphosphate glucuronic acid [7]. 4-MU also downregulates
HAS2 and HAS3 expression [12]. Recent studies showed
that 4-MU had an antitumor effect on prostate, breast,
and hepatocellular carcinomas through the inhibition of
HA synthesis [13-15]. Therefore, the CD44-HA inter-
action may be a promising target for therapeutic interven-
tion of metastases. However, the clinical implications of
4-MU administration and ovarian cancer growth have not
been investigated.
This study was conducted to investigate the antitumor
potential of 4-MU against human ovarian cancer cells
and to elucidate its mechanism of action.
Methods
Chemicals and cell culture
4-MU was purchased from Tokyo Chemical Industry
(Tokyo, Japan). HRA cells, which were derived from a
human ovarian serous adenocarcinoma [16], were kindly
provided by Dr. Y. Kikuchi (National Defense Medical
College, Japan) and were maintained in RPMI 1640
medium (Invitrogen, Tokyo, Japan) supplemented with
10% fetal bovine serum (FBS), 100 U/ml penicillin, and
100 μg/ml streptomycin at 37°C in a humidified atmos-
phere with 5% CO2/95% air. This cell line was authenti-
cated as being ovarian in origin with a written guarantee.
4-MU stock solution for in vitro experiments was dis-
solved in medium containing 1% dimethylsulfoxide
(DMSO) (Sigma-Aldrich, St Louis, MO) and the final con-
centration of DMSO in the medium was adjusted to 0.1%.
Ethics statement
Animal experiments were approved by the Animal Re-
search Committee of Hirosaki University (M13024) andall animals were cared for and handled in accordance
to the Rules for Animal Experimentation of Hirosaki
University and animal practices as defined by the na-
tional and local animal welfare bodies (Guide for the
Care and Use of Laboratory Animals published by the
National Institutes of Health). Animals were sacrificed
according to the Guidelines for Euthanasia of Rodents
using carbon dioxide.
Peritoneal carcinomatosis model
Eight-week-old female F344/NJcl-rnu/rnu nude rats
(CLEA Japan, Inc., Tokyo, Japan) were used in this study.
Rats were group-housed in plastic cages with stainless-
steel grid tops under a 12-hour light/dark cycle and
given free access to water and food. Laparotomy was
performed under sterile conditions and with general
anesthesia using pentobarbital. Anesthesia was main-
tained up to 30 minutes with good analgesia and muscle
relaxation. The omentum was accessed via a 4-cm mid-
line incision in the abdomen and subsequently extir-
pated by ligating the gastroepiploic vessels and hilum of
the spleen [17]. After hemostasis, the abdominal wall
was closed in 2 layers by using 3/0 polyglactin (Vicryl®,
Ethicon, Tokyo, Japan). No animals died as a result of
the operative procedure. On the second day after sur-
gery, HRA cells (3.7 × 107 cells) were inoculated into the
peritoneal cavity of the rats by injecting cells intraperito-
neally with a 22-gauge needle. The rats were divided into
2 groups (n = 5 each). In the 4-MU-treated group, rats
were administered 4-MU (100 mg per body) dissolved in
2.0 ml of 0.4% carboxymethylcellulose (CMC) solution
(Sigma-Aldrich) intraperitoneally daily starting on the
day when the cells were inoculated. The same volume of
0.4% CMC solution without 4-MU was administered
intrapetitoneally to the rats in the control group. We
allowed a subset of animals from each group to survive
until the humane endpoints defined by inability to access
food or water or increased effort due to progressing ab-
dominal ascites. Rats were sacrificed by carbon oxide as-
phyxiation at the defined humane endpoints. Their
health conditions were observed daily and all efforts
were made to minimize suffering.
Cell proliferation assay
Cell proliferation was assayed by using a Cell Counting
Kit-8 (CCK-8; Dojin Laboratories, Kumamoto, Japan).
HRA cells were cultured overnight in 96-well micro-
plates at 2 × 103 cells per well with 100 μl of medium.
Further, the cells were treated with 0, 0.2, 0.6, and
1.0 mM 4-MU and cultured for 72 hours. Cell viability
was assessed 3 hours after the addition of CCK-8 by
measuring A450 with a Multiskan FC microplate reader
(Thermo scientific, Yokohama, Japan). A preliminary
study using this kit showed that absorbance was directly
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conducted 5 times.
Cell invasion and migration assay
Cell invasion and migration were assessed with a Cyto-
select Cell Invasion Assay (Cell Biolabs, Inc., San Diego,
CA) and a Cytoselect Cell Migration Assay (Cell Biolabs,
Inc.), respectively, according to the manufacturer’s
protocol. For invasion assays, HRA cells (1.0 × 105 cells
per well) in serum-free medium containing 0, 0.2, 0.6, or
1.0 mM 4-MU were placed in the upper chamber, which
had an 8.0-μm pore size membrane coated with a uni-
form layer of basement membrane matrix solution, and
medium with 10% FBS was placed in the lower chamber.
After 24 hours, the cells from the underside of the mem-
brane were removed by tilting the membrane chamber
in Cell Detachment Solution. Lysis Buffer/CyQUANT
GR dye solution was added to each well and the fluores-
cence of the mixture was measured by using a fluores-
cence plate reader (Fluoroskan Ascent, Thermo Scientific)
at excitation and emission wavelengths of 480 nm and
520 nm, respectively. For migration assays, HRA cells
(1.0 × 105 cells per well) in serum-free medium containing
0, 0.2, 0.6, or 1.0 mM 4-MU were placed in the upper
chamber, which had an 8.0-μm pore size membrane
without basement membrane matrix solution, and
medium with 10% FBS was placed in the lower cham-
ber. After 3 hours, the cells that had migrated to the
lower surface were quantified by using CyQUANT GR
dye as described above. Each experiment was performed
in triplicate.
Real-time quantitative polymerase chain reaction (qPCR)
Expression levels of HAS2, HAS3, CD44, vascular endo-
thelial growth factor (VEGF), and thymidine phosphoryl-
ase (TP) were determined in HRA cells cultured with or
without 1.0 mM 4-MU for 24 hours. Total RNA was ex-
tracted from the cells by using an Illustra RNAspin Mini
RNA Isolation Kit (GE Healthcare, Piscataway, NJ) and
cDNA was synthesized with an iScript Advanced cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). Real-time qPCR
was performed by using a CFX96 real-time PCR detec-
tion system (Bio-Rad) and a SsoAdvanced SYBR Green
Supermix solution (Bio-Rad), according to the manufac-
turer’s specifications. The amplification conditions were
as follows: 30 seconds at 95°C, followed by 95°C for
5 seconds and 60°C for 30 seconds for 40 consecutive
cycles. After amplification, a melting curve from 65°C to
95°C at 0.5°C increments and 5 seconds per step was
generated with continuous monitoring of fluorescence.
The melting curves and quantitative analysis of the data
were performed by using CFX manager Version 2.1 soft-
ware (Bio-Rad). The mRNA levels of HAS2, HAS3,
CD44, TP, and VEGF in a sample were normalized tothe amount of 18S rRNA [18]. The sequences of the
primers were as follows:
HAS2 forward, 5′-CAGCCTCATCTGTGGAGATGG
TAA-3′
HAS2 reverse, 5′ -CCAGAGGTCCACTAATGCACTG
AA-3′
HAS3 forward, 5′ -TGCGACTCTGACACTGTGCTG-3′
HAS3 reverse, 5′ -GGAAATCCATGAGTCGTACTTG
TTG-3′
CD44 forward, 5′ -CTCCGGACACCATGGACAA-3′
CD44 reverse, 5′-CCACGTGGAATACACCTGCAA-3′
TP forward, 5′-GGCTGCTGTATCGTGGGTCA-3′
TP reverse, 5′ -GAACTTAACGTCCACCACCAGAG-3′
VEGF forward, 5′-TGGAGTGTGTGCCCACTGAG-3′
VEGF reverse, 5′- TGCATTCACATTTGTTGTGCTGT
AG-3′
18S rRNA forward, 5′-ACTCAACACGGGAAACCTCA-3′
18S rRNA reverse, 5′ -AACCAGACAAATCGCTCCAC-3′
Specific primer sets for HAS2, HAS3, CD44, VEGF,
and TP were purchased from Takara Bio, Inc. (Otsu,
Japan). 18S rRNA specific primers were purchased from
FASMAC (Atsugi, Japan).
Western blot analysis
Cell lysates (50 μg protein) were prepared from cultured
HRA cells treated with 0, 0.2, 0.6, and 1.0 mM 4-MU for
72 hours, electrophoresed through a 12.5% sodium do-
decyl sulfate polyacrylamide gel, and blotted as described
previously [19]. The protein concentration was deter-
mined using Bradford’s method. The blots were probed
with the following diluted antibodies for 2 hours: TP
(Proteintech, Chicago, IL) (Catalog number: 12383-1-
AP) at 1:1000 and β-actin (Sigma-Aldrich) at 1:2000.
The membranes were then incubated for 1 hour with
the appropriate biotinylated secondary antibodies, trans-
ferred to avidin-biotin-peroxidase complex reagent, and
incubated in this solution for 30 minutes. Diaminobenzi-
dine was used as a substrate.
Statistical analysis
Survival rates were calculated by using the Kaplan–Meier
method and the statistical significance of differences in the
cumulative survival curves between the groups was evalu-
ated using the Wilcoxon test. Other statistical analyses
were carried out with Student’s t-test. P values < 0.05 were
considered statistically significant.
Results
Anti-tumor effect of 4-MU in a peritonitis carcinomatosa
model
The survival periods of the control and 4-MU-treated
groups were compared. All rats in the control group
died by day 13. 4-MU administration in the 4-MU-
treated group was discontinued after day 14 and survival
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vival times were significantly longer in the 4-MU-treated
group than in the control group (P < 0.05, Figure 1A).
Hemorrhagic ascites developed in the control group,
whereas they were absent or mild in the 4-MU-treated
group. Therefore, there was significant difference in
body weight gain between the 2 groups (Figure 1B). As
shown in Figure 1C, peritoneal tumors developed in the
control group. Two rats in the 4-MU-treated group
survived for 5 weeks and were sacrificed with carbon
dioxide as described in Ethics statement section, al-
though they reached the defined humane endpoints at
the experimental endpoint. The post-mortem examin-
ation showed that their intraperitoneal tumors were
much smaller than those in the control rats even though
4-MU administration was discontinued after day 14
(Figure 1C). Neither pleural effusion nor pleural metas-
tasis was observed in both groups.
Effects of 4-MU on cell proliferation, invasion, and migration
Figure 2A shows cell viability assessed by measuring A450
with a Multiskan FC microplate reader 3 hours after the
addition of CCK-8. The cell viability of control cells had





















Figure 1 Anti-tumor effect of 4-MU in a peritonitis carcinomatosa mo
survival times were significantly prolonged in the 4-MU-treated group com
difference in body weight gain between the 2 groups due to increased ma
the 2 groups. Rats in the control group developed large peritoneal tumors
The arrows indicate peritoneal tumors.after plating, while proliferation of cells treated with 0.2,
0.6, or 1.0 mM 4-MU decreased over time, suggesting that
4-MU significantly inhibited the proliferation of HRA cells
in a dose-dependent manner. However, 4-MU treatment
did not affect cell invasion or migration (Figure 2B and C).
Altered TP protein and mRNA expression levels in HRA
cells treated with 4-MU
Western blot analysis showed that 4-MU reduced TP pro-
tein level in a dose-dependent manner (Figure 3A). Real-
time quantitative PCR confirmed a significant reduction of
TP mRNA expression level in HRA cells treated with
1.0 mM 4-MU, whereas no significant difference in HAS3
expression was observed between HRA cells cultured with
and without 4-MU (Figure 3B). Since HAS2, CD44, and
VEGF endogenous mRNA expression levels were very low
in HRA cells although their expression levels were high in
U373MG human astrocytoma cells [18] and SH-SY5Y hu-
man neuroblastoma cells [20], it was impossible to evalu-
ate the effect of 4-MU treatment (data not shown).
Discussion
Survival was significantly prolonged by the administra-




























del. (A) Rats in the control group did not survive after day 13. The
pared with the control group (P < 0.05). (B) There was a significant
lignant ascites. *P < 0.05 (C) Differences in peritoneal tumors between
, whereas tumor sizes were smaller in rats in the 4-MU-treated group.
Figure 2 Effects of 4-MU on cell proliferation, invasion, and migration. (A) 4-MU significantly inhibited the proliferation of HRA cells in
a dose-dependent manner. 4-MU did not affect cell invasion (B) and migration (C). *P < 0.005 versus control, ♯P < 0.0001 versus control,
‡P = 0.0000 versus control, †P < 0.0001 versus 0.2 mM, § P = 0.0000 versus 0.2 mM, ¶P = 0.0000 versus 0.6 mM.
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showed potential for reducing peritoneal dissemination
of tumors as well as malignant ascites production. Rats
were not administered 4-MU after day 14; however, the
effect lasted until the end of the experiment. Although
the rats that survived for 5 weeks had small peritoneal
masses, there were no malignant ascites in their abdo-
men, suggesting that 4-MU treatment inhibits implant-
ation and proliferation of malignant cells in these
animals. Because 3 of the 4-MU-treated rats died of
peritonitis carcinomatosa by day 13, technical aspects
such as administration route and optimal dose of 4-MU
must be reconsidered.
In the in vitro experiments, 4-MU inhibited prolifera-
tion of HRA cells in a dose-dependent manner, support-
ing previous results obtained in other types of cancer
cells [13-15,21,22]. Although previous studies showed
that 4-MU inhibited cancer growth by inhibiting cell in-
vasion and migration [11,12,22], the present study didnot show an effect of 4-MU on HRA cell invasion and
migration. Although counting the number of cells that
moved to lower membrane by staining with hematoxylin
might be more appropriate in order to detect a little dif-
ference, this discrepancy may be partly accounted for by
the absence of CD44 receptors on the surface of HRA
cells. 4-MU is shown to elicit its action through inhibit-
ing HAS that plays an important role in tumor growth
via binding to CD44 receptors located on surface of can-
cer cells. Moreover, Day and Prestwich [23] suggested
the existence of other receptors, indicating that 4-MU
might exert its anti-proliferative effect directly or via an
unknown receptor.
The antitumor mechanism of 4-MU remains poorly
understood. HA, which is a high-molecular-weight gly-
cosaminoglycan and a major component of extracellular
matrix, promotes tumor proliferation, invasion, and mi-
gration by binding to the CD44 HA receptor [24]. HA is


















































































Figure 3 4-MU treatment altered TP protein and mRNA expression levels in HRA cells. (A) Western blot showed a reduction of TP protein
in a dose-dependent manner of 4-MU. MW abbreviated molecular weight. (B) 4-MU administration significantly reduced the TP mRNA expression
level in HRA cells (left panel), whereas there was no significant difference in HAS3 expression between HRA cells cultured with and without 4-MU
(right panel). The relative expression of TP and HAS3 mRNA was analyzed by qRT-PCR in HRA cells cultured with or without 1.0 mM 4-MU for
24 hours. The data presented are the average ± SD of the relative mRNA expression values normalized to the 18S rRNA amount (*indicates
P = 0.0005 compared with control).
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Anttila et al. [26] reported that high levels of stromal
HA predict poor prognosis in patients with epithelial
ovarian cancer. It is known that the HA-CD44 inter-
action can lead to the activation of intracellular signaling
pathways such as PI3K/Akt that affect the proliferation,
migration, and invasion of cancer cells [27]. Recently,
CD44 was shown to be a cancer stem cell marker [10],
and it was reported that CD44 could promote cell motil-
ity and tumorigenicity [11]. Earlier studies suggested that
4-MU exerted its antitumor activity by downregulating
HAS and CD44 mRNA levels, leading to inhibition of
HA synthesis as well as HA-CD44 binding [13]. How-
ever, this study revealed that HRA cells expressed ex-
tremely low levels of HAS2 and CD44 mRNA and that
the expression level of HAS3 mRNA in HRA cells was
low and was not altered by 4-MU administration, so HA
production was not determined in this study. These re-
sults suggest that the anti-tumor effect of MU is
dependent on a mechanism other than HA-CD44 signal-
ing. Since hepatocellular carcinoma (HCC) generally
arises in a cirrhotic liver, it is important to investigate
HCC development in association with a fibrotic micro-
environment [15]. 4-MU has anti-fibrogenic activity.
Piccioni et al. [15] reported that 4-MU might be an anti-cancer agent for HCC associated with advanced fibrosis
because it induced apoptosis of hepatic stellate cells
(HSCs), which play a key role in advancing liver fibrosis,
and decreased the number of activated HSCs. Saito et al.
also reported that 4-MU inhibited cell proliferation and
induced apoptosis in breast cancer cells together with
inhibiting HA synthesis accompanied by downregulation
of HAS2 mRNA levels in a dose-depending manner
[28]. Therefore, 4-MU may have different anti-tumor
mechanisms depending on the type of cancer.
It is well known that progression and metastasis of ovar-
ian cancer are largely attributable to the activity of differ-
ent angiogenic factors [29,30] and that the main route of
development of this disease is via peritoneal dissemination
with malignant ascites [19]. A recent study indicated that
4-MU inhibited angiogenesis in vitro and in vivo [31].
Thus, we determined the expression levels of VEGF and
TP in HRA cells cultured with or without 4-MU. VEGF is
a multifunctional cytokine and it is well known as an an-
giogenic factor [32]. Bevacizumab, a monoclonal antibody
against VEGF, is used clinically as a treatment for ovarian
cancer [3]. TP catalyzes the reversible phospholysis of thy-
midine, deoxyuridine, and their analogs to their respective
bases and 2-deoxyribose-1-phosphate [33]. TP is identical
to platelet-derived endothelial cell growth factor and has
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cancer patients is associated with a poor prognosis [35].
Tsukagoshi et al. [36] reported that angiogenesis in ovarian
serous adenocarcinoma cell lines, including HRA, is
dependent on TP mRNA expression and treatment with a
TP inhibitor could block angiogenesis in those cell lines.
Recently, some studies suggested that TP has an anti-
apoptosis activity in addition to its angiogenic activity
[37,38]. The present study showed that although HRA
cells did not express VEGF mRNA, TP mRNA expression
was significantly decreased by 4-MU treatment, suggesting
that decreased TP expression may be involved in the in-
hibitory effect of 4-MU on ovarian cancer. Ko et al. [39]
reported that PI3K/Akt signaling regulated TP expression.
Therefore, 4-MU might inactivate PI3K/Akt signaling by
suppressing a ligand-receptor interaction different from
the HA-CD44 interaction.
To our knowledge, this is the first study to report an
inhibitory effect of 4-MU on ovarian cancer. Although
earlier studies showed that 4-MU exhibited its anti-
tumor activity by suppressing the HA-CD44 interaction,
this study demonstrated that 4-MU downregulated TP
expression in ovarian cancer cells. This suggests that
4-MU may act as an angiogenesis inhibitor and have po-
tential as a new drug in the therapeutic strategy for ovar-
ian cancer.
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